Azure partnership Strategic alignment with Microsoft Azure and cloud-native Climb positions RockStep to offer scalable, compliant in vivo study management on a trusted cloud platform, enabling joint value propositions for large pharma and CROs seeking robust cloud integration and security.

Acquisition signal Recent acquisition news indicates a potential shift in go-to-market and product focus. Sales teams should anticipate channel realignments and explore opportunities with Instem to complement or accelerate existing client deployments in life sciences data management.

Funding & growth Past Series A funding and NIH SBIR-backed origins demonstrate investor confidence and growth potential. This suggests expanding the sales motion toward fast-growing biotech, biopharma, and CRO segments looking for modern, scalable preclinical data platforms.

Clinical workflow fit Climb’s emphasis on real-time visibility across in vivo study workflows, vivarium management, and data harmonization creates a compelling pitch for mid-size to large biotech and CRO customers seeking to replace spreadsheets and legacy systems with integrated study software.

Small team agility With a lean team profile, RockStep can partner with system integrators and niche service providers to co-sell or white-label solutions, enabling faster market reach into pharma and biotech accounts that value rapid deployment and specialized expertise.